Improving the effectiveness of Tarlatamab for treating small cell lung cancer
Official title: A Novel Approach to Enhance Therapeutic Efficacy of Tarlatamab for Small Cell Lung Cancer Treatment
Funded at University of Alabama at Birmingham · NIH-11093082 · Data updated 2026-11-12
This study is looking to make the cancer treatment Tarlatamab work better for people with small cell lung cancer by figuring out what helps some patients respond well to it, so they can create more personalized and effective treatment plans.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $208,271 |
| NIH project number | 1R21CA298890-01 |
| Project ID | NIH-11093082 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with small cell lung cancer who have previously received treatment and are seeking new therapeutic options.
✕Less likely to help
Patients with other types of lung cancer or those who have not been previously treated for small cell lung cancer may not benefit from this research.
What this research studies
This research focuses on enhancing the therapeutic effects of Tarlatamab, a bispecific T-cell engager antibody, for patients with small cell lung cancer (SCLC). The study aims to identify molecular factors that influence how well patients respond to Tarlatamab, which targets specific cancer cells and activates the immune system to fight the tumor. By understanding these drivers of response, the research seeks to optimize treatment strategies and improve patient outcomes. The approach involves analyzing patient samples and utilizing advanced technologies like CRISPR to better tailor therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with small cell lung cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with bispecific T-cell engagers in other cancers, indicating potential for success with this novel approach in small cell lung cancer.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Wajapeyee, Narendra — University of Alabama at Birmingham
- Study coordinator: Wajapeyee, Narendra
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.